Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2005

View Archived Issues

Clearance for phase I study of 1D09C3 in Germany

PainCeptor selects preclinical development lead candidates for key programs

Edison receives FARA grant to develop EPI-A0001 for Friedreich's ataxia

CTCE-9908 prevents human prostate cancer metastases in preclinical study

New phase I study for Heplisav HBV vaccine

Epitan reports results from European PMLE phase II study of EPT-1647

Weight loss seen in phase I study of oleoyl-estrone

Nicholas Piramal to acquire Avecia Pharmaceuticals

InterMune enrolls 600th patient in pivotal INSPIRE study

Approval for phase I study in Stem Cell Therapeutics' stroke program

European phase II trial studies Uvidem for melanoma

Aphton and sanofi pasteur to terminate Insegia agreements

European approval for Zeldox for manic or mixed episodes in bipolar disorder

Recent Ligand patent discloses novel androgen receptor modulators

Recent patents cover novel treatments for neurological disorders

Boehringer Ingelheim patents novel agents for treating inflammation

AVE-8062 reported to prevent proliferation of solid tumors in rats

KLF5 antagonists may play a role in the treatment of vascular diseases

SELENBP1 identified as candidate gene for schizophrenia using novel approach

New broad-spectrum antibiotics with a novel mechanism of action

Lentivirus-mediated gene therapy for sickle cell anemia and thalassemia to soon enter clinical trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...